"During the seven years from initial establishment to gradual growth, it can be said that the company has experienced a leap-forward development process. In addition to the excellent situation of national economic development, it is particularly valuable that our team is determined and persistent in taking the road of independent innovation. " General Pu's words reveal the heroic spirit of entrepreneurs and the courage of a scientific researcher.
At the end of November, 25, Lepu Company officially obtained the product registration certificate of "Rapamycin Drug-eluting Coronary Stent Delivery System" issued by National Medical Products Administration. Since it was officially listed for nearly five months, it has produced more than 1, drug stents, with a sales income of more than 5 million yuan. Only in December, 25, the tax paid was 1.2 million yuan, with remarkable economic benefits. The company achieved sales in 24 and 25 compared with the previous year.
after seven years of tempering, at present, lepu company has 22 national patents, 11 Class III medical device products and 2 Class I products issued by the State Food and Drug Administration, and has the industrial production capacity of cardiovascular intervention, anesthesia monitoring and nursing. Products include coronary stents, PTCA balloon catheters, arterial sheaths, ultra-smooth guide wires, central venous catheters (CVC, PICC), pressure sensors, infusion pumps and blood gas sampling boxes, etc. Recently, PARTNER drug-eluting coronary stents have been successfully listed, and the product sales network covers all provinces and cities in China except Tibet.
"Where does the company's future road point? I believe every employee in Lepu will have a clear direction." Talking about the prospect of the enterprise, Mr. Pu believes that Lepu will form a good situation of product serialization, brand internationalization, talent echelon and sales network on the premise of double guarantee of technology and quality, utilize government resources and the technology, talent and market resources that the enterprise already has, integrate the existing medical device resources in Beijing, break foreign monopoly and effectively restrict the price of foreign products, so that more patients in China can really widely use interventional medical products and build a domestic first-class national brand of medical devices. The development of all products is first of all to better serve people, put people first and respect people's personality, which is very important. At present, when researching and developing many high-tech products in the west, we should consider how to better meet the characteristics and needs of human nature, and whether the production process will cause damage to the human ecological environment. This idea is worth learning from China researchers.
Pu Zhongjie, the head of Lepu, whose foundation is honesty, high quality and scientific innovation, revealed a strong humanistic knot at the beginning of the interview, which was unexpected, but at the same time deepened the reporter's interest in Pu Zhongjie and his medical career. (Hexun Finance was founded in 1999, which was jointly funded by the 725th Research Institute of China Shipbuilding Industry Corporation and WP Company of the United States. As the founder of the company, Pu Zhongjie has always attached the company to the name of China Ship. Lepu (Beijing) Medical Equipment Co., Ltd. was established in 1999, which was jointly funded by the 725th Research Institute of China Shipbuilding Industry Corporation and WP Company of the United States. The company is mainly engaged in the research, development, production and sales of coronary intervention medical devices, and it is one of the few enterprises that can form strong competition with foreign products in the field of high-end medical devices in China. Since its establishment, the company has successively completed the research, development and industrialization of a number of interventional medical core products, such as stents and catheters. It is the first in the industry to obtain the product registration certificate of "coronary stent delivery system" (Class III) issued by National Medical Products Administration, and the first to successfully develop and trial-produce the anti-infection "drug central venous catheter". The main products of Lepu (Beijing) Medical Devices Co., Ltd. include intravascular drug (rapamycin) eluting stent system, coronary stent delivery system, PTCA balloon dilatation catheter, drug central venous catheter and so on. The main products of Tiandi Xiehe, the holding subsidiary of the company, are anesthetic interventional medical products, sheaths and guide wires for cardiac interventional surgery, etc. The main products of Shanghai Shape, a holding subsidiary, are patent ductus arteriosus (PDA) occluder, atrial septal defect (ASD) occluder and ventricular septal defect (VSD) occluder. Lepu (Beijing) Medical Devices Co., Ltd. has 9 class III medical device product registration certificates issued by National Medical Products Administration, 1 class II medical device product registration certificate issued by Beijing Food and Drug Administration, 2 class I medical device product registration certificates issued by Beijing Food and Drug Administration, and 2 product registration certificates that are being applied for approval. It is an early domestic enterprise with rapamycin drug stent coating technology, and one of the few domestic enterprises with independent technology to produce and process balloon dilatation catheters and contrast catheters. Around the drug stent and its supporting products, the company has 36 patents approved by the state, and 3 applications are pending (4 of which are applying for international patents).
Shanghai Shapes and Shanghai Shapes, the holding subsidiaries of the company, are mainly engaged in the research, development, production and sales of cardiac interventional occluder medical devices. They are one of the major manufacturers of cardiac occluder products in China, with 5 class III medical device product registration certificates issued by National Medical Products Administration and 8 national patents.
Tiandi Xiehe, a holding subsidiary of Lepu (Beijing) Medical Devices Co., Ltd., is mainly engaged in the research, development, production and operation of medical devices such as interventional anesthesia monitoring and interventional accessories. It has 7 class III medical device product registration certificates issued by National Medical Products Administration, 1 class I medical device product registration certificate issued by Beijing Food and Drug Administration, 4 class II medical device product registration certificates, and is applying for 4 national patents to be approved.
the company established a strict medical device quality management system according to national and medical industry standards GB/T191 and YY/T287, and passed the certification in 24. In 27, the company became the first stent system manufacturer in China to pass the GMP pilot inspection and audit in National Medical Products Administration.
lepu (Beijing) medical device co., ltd is located in Changping science and technology park, Zhongguancun science and technology park. it has been recognized as "Beijing high-tech enterprise", "Zhongguancun science and technology park 1 innovative pilot enterprises" and "Beijing municipal enterprise technology center", and has been named as "the most growing enterprise in new material industry in 26", and has become the executive director of the surgical implant professional Committee of China Medical Device Industry Association. In January 29, the company was awarded the title of "Beijing Municipal Enterprise Technology Center". In March 29, the company was awarded the title of "Outstanding Contribution Enterprise Unit of Zhongguancun 2th Anniversary"; In June 29, the company won the "Beijing Famous Trademark". In line with the enterprise spirit of "honesty, high quality, science and innovation", Lepu (Beijing) Medical Devices Co., Ltd. will wholeheartedly provide the best quality products and services for the majority of medical personnel and patients, and strive to build a first-class national brand of interventional medical devices in China. On September 18th, 26, he donated RMB 1, to China Society of Biomedical Engineering.
on July 5, 27, 522 coronary stents worth 6 million yuan were donated to the China Foundation for the Development of Aging, which was used for the large-scale public welfare activity of "Caring Care Fund-Kindness Action" of the China Foundation for the Development of Aging.
in may, 28, all the colleagues of lepu medical co., ltd spontaneously organized a donation activity of "United efforts for earthquake relief" to help the people affected by the Wenchuan earthquake in Sichuan, and donated 32,835 yuan that day, which was quickly donated to the disaster area through the Changping red cross society in Beijing.
in may, 28, lepu medical donated RMB 3, in the "Wenchuan rescue operation" launched by Beijing red cross society, and timely allocated 1 sets of central venous catheter products for intensive care for disaster relief in Sichuan earthquake-stricken areas.
in June p>28, the company donated 2, yuan in cash to Pengzhou Municipal Health Center through Chengdu Health Bureau for disaster relief in Sichuan earthquake-stricken areas.
in April, 29, the company launched the donation activity of cardiac occluder to help children from poor families nationwide. The Lepu Children's Aid Society donated 1 million yuan for the operation of the project, and the Children's Aid Society will certainly make good use of this money and make greater contributions to more children in need of assistance. On behalf of china association of social workers, Executive Vice President Yang Jianchang, Vice President and Secretary General Zhao Pengqi and Vice President Liu Liangyu presented honorary certificates to General Manager Pu Zhongjie to thank Lepu (Beijing) Medical Devices Co., Ltd. for its contribution to the field of congenital heart disease in children.
On the morning of March 31st, 21, the donation ceremony between Lepu Company and china association of social workers Children's Rescue Committee was held in the conference room on the third floor of china association of social workers. Executive Vice President Yang Jianchang, Vice President and Secretary General Zhao Pengqi, Vice President Liu Liangyu, Director General of china association of social workers Children's Rescue Committee Wu Jianying, Deputy Director Zhang Wen, Director of "Love Hope" Medical Aid Project Office Wang Lingyan, Deputy Director Zhang Yuhuan and General Manager Pu Zhongjie and Shanghai Shape of Lepu (Beijing) Medical Devices Co., Ltd.
On April 21st, 21, Lepong sent the first donation of RMB 1, to the victims in Yushu through the Scarlet Letter Society in Changping District.